When you eat cannabis, your liver converts THC into 11-hydroxy-THC — a metabolite with roughly 100 times higher receptor binding affinity that crosses the blood-brain barrier more efficiently, explaining why edibles feel more intense and last longer.
Anyone who has ever been surprised by the intensity of an edible, cannabis consumers choosing between consumption methods, medical patients considering oral cannabis, and anyone interested in how the body processes drugs.
11-OH-THC binds CB1 receptors roughly 100 times more tightly than delta-9-THC — the liver does not just process cannabis, it amplifies it.
The Backstory
The story always starts the same way. Someone eats a cannabis edible — a gummy, a brownie, a chocolate bar. They wait 30 minutes and feel nothing. They eat another piece. An hour after the first dose, both hit simultaneously and the experience is nothing like smoking. It is deeper, more physical, more intense, and it lasts for hours. Some people love it. Some people end up in the emergency room.
The pharmacological reason this happens has been known since 1972. A researcher named Louis Lemberger, working at the National Institute of Mental Health, published a three-page paper in Science that identified the molecule responsible: 11-hydroxy-THC. When you eat cannabis, your liver does not just process the THC — it converts it into something more potent.
The Man Who Mapped THC Metabolism
Louis Lemberger earned both his MD and PhD in Pharmacology from Albert Einstein College of Medicine. During the Vietnam War era, he served as a Commissioned Officer in the U.S. Public Health Service at the NIH's National Institute of Mental Health — an assignment that put him at the center of the government's interest in understanding cannabis pharmacology.
In two years at NIMH, Lemberger published roughly a dozen papers on THC, many as first author, in the most prestigious journal in science. Three of them appeared in Science in rapid succession:
- 1970: The first study of THC disposition and metabolism in humans — establishing that delta-9-THC persists in plasma for more than 3 days with a half-life of 56 hours
- 1971: Differences between chronic cannabis users and naive subjects — chronic users cleared THC from blood with a half-life of 28 hours versus 57 hours in nonusers
- 1972: The 11-OH-THC paper — identifying the active metabolite that would explain why edibles feel different from smoking
In 1971, Lemberger moved to Eli Lilly in Indianapolis, where he became Director of Clinical Pharmacology. The career that followed reads like a pharmacological hall of fame: he was the first physician to administer Prozac (fluoxetine), Zyprexa (olanzapine), Cesamet (nabilone — a synthetic cannabinoid for chemotherapy nausea), Strattera (atomoxetine), and Permax (pergolide) to a human being. The man who decoded how the body processes cannabis went on to develop the world's most successful antidepressant.
The First-Pass Problem
When you smoke or vape cannabis, THC enters your lungs and passes directly into your bloodstream. Within seconds, it reaches your brain. Your liver eventually metabolizes it, but most of the initial dose hits cannabinoid receptors as delta-9-THC — the molecule in the plant.
When you eat cannabis, the path is entirely different.
Process
What Happens When You Eat Cannabis
Stomach & Small Intestine
THC is absorbed through the gut lining into the portal vein — the blood vessel that carries everything from your digestive tract directly to the liver. This absorption takes 30 minutes to 2 hours depending on stomach contents, fat intake, and individual variation.
First-Pass Liver Metabolism
Before THC reaches your brain, it passes through the liver. The enzyme CYP2C9 hydroxylates delta-9-THC at the C-11 position, converting it to 11-hydroxy-THC (11-OH-THC). When smoking, much less THC undergoes this conversion because it bypasses the liver initially.
11-OH-THC Enters the Bloodstream
The converted metabolite enters systemic circulation alongside whatever unconverted THC remains. After oral consumption, the ratio of 11-OH-THC to THC is much higher than after smoking — the liver has converted a substantial fraction.
11-OH-THC Reaches the Brain
11-OH-THC crosses the blood-brain barrier more efficiently than delta-9-THC because it is more hydrophilic. Once there, it binds CB1 receptors with dramatically higher affinity. The result is a more intense, longer-lasting experience.
Lemberger et al. (1972), Science 177:62-64; subsequent pharmacokinetic studies
The Numbers That Explain Everything
~100x
higher binding affinity at CB1 receptors. Later receptor binding studies found 11-OH-THC has a Ki of approximately 0.37 nM at the CB1 receptor, compared to roughly 35 nM for delta-9-THC. This means 11-OH-THC grabs onto the same receptor roughly 100 times more tightly. Combined with better blood-brain barrier penetration, this makes the oral metabolite substantially more potent per molecule than the parent compound.
For context, this is not a subtle difference. It is comparable to the potency gap between a regular beer and a shot of high-proof liquor — the same active ingredient, dramatically concentrated by metabolic processing.
Receptor binding data from subsequent studies; potency estimates from animal models suggest 2-7x greater psychoactive effect
Smoked/Vaped Cannabis
- THC absorbed through lungs → directly to bloodstream → brain within seconds
- Bypasses first-pass liver metabolism initially
- Low 11-OH-THC/THC ratio — most of the psychoactive effect is from delta-9-THC itself
- Onset: 1-5 minutes, peak effect: 15-30 minutes
- Duration: 2-4 hours typically
- Easier to self-titrate: you feel effects quickly and can stop
Faster, shorter, more controllable
Eaten Cannabis (Edibles)
- THC absorbed through gut → portal vein → liver first-pass → then bloodstream → brain
- Heavy first-pass metabolism: CYP2C9 converts much THC to 11-OH-THC
- High 11-OH-THC/THC ratio — the more potent metabolite dominates the experience
- Onset: 30 minutes to 3 hours depending on stomach contents
- Duration: 4-8+ hours, sometimes longer
- Difficult to self-titrate: delayed onset invites accidental redosing
Slower, longer, more intense, harder to control
Lemberger et al. (1972); modern pharmacokinetic reviews
Why People Get Into Trouble
The delayed onset is the practical danger of this pharmacokinetic pathway. When you smoke cannabis and it is too strong, you know within minutes. When you eat an edible that is too strong, you may not know for an hour or more — by which time many people have taken a second dose.
The same pharmacokinetics explain several other edible-specific phenomena:
- Why edible withdrawal can feel different: 11-OH-THC has a longer half-life than delta-9-THC, so it takes longer to clear the system. Regular edible users may have higher steady-state levels of the more potent metabolite.
- Why edibles feel more "body-heavy": The qualitative difference consumers report is likely related to the different receptor binding profile of 11-OH-THC versus THC.
- Why THC stays in your system so long: Lemberger's original 1972 paper showed drug and metabolites excreted for more than one week. Cannabis metabolites are lipophilic, stored in fat tissue, and released slowly.
- Why sublingual products hit faster than edibles: THC absorbed under the tongue enters the bloodstream directly, partially bypassing first-pass liver metabolism. Less 11-OH-THC is formed, so the experience is somewhere between smoking and eating.
The Broader Legacy
Lemberger's three papers in Science (1970, 1971, 1972) established cannabinoid pharmacokinetics as a scientific field. Before his work, virtually nothing was known about how the human body processed THC — a compound that Mechoulam had isolated just eight years earlier.
Research Timeline
From THC Isolation to Understanding Metabolism
Mechoulam & Gaoni isolate and synthesize THC
Identified the molecule but nothing was known about how the body processes it
Lemberger et al.: THC disposition in man (Science)
First human study showing THC persists in plasma for >3 days with a 56-hour half-life
Lemberger et al.: Chronic vs naive users (Science)
Chronic users clear THC faster (28-hour vs 57-hour half-life) — the first pharmacokinetic evidence that tolerance has metabolic as well as receptor-level components
Lemberger et al.: 11-OH-THC identified (Science)
Demonstrated that the liver metabolite is pharmacologically active and responsible for the distinct effects of oral cannabis
Cesamet (nabilone) FDA approved
Lemberger, now at Eli Lilly, developed the first cannabis-based pharmaceutical — a synthetic cannabinoid for chemotherapy nausea
Prozac (fluoxetine) FDA approved
Lemberger was the first physician to administer Prozac to a human. The man who decoded THC metabolism also launched the SSRI revolution
Legal edibles market creates mass-scale relevance
Colorado and Washington legalize recreational cannabis. Edible dosing guidelines are built directly on the pharmacokinetics Lemberger established 40 years earlier
Lemberger et al. (1970, 1971, 1972); Eli Lilly corporate history; Nature Neuropsychopharmacology obituary (2016)
What makes Lemberger's career trajectory remarkable is the through-line: he went from NIMH mapping how the body processes cannabis to Eli Lilly developing actual cannabis-derived medicine (Cesamet). The same pharmacokinetic expertise that produced the 11-OH-THC paper produced nabilone — a synthetic cannabinoid that proved cannabis compounds could be pharmaceutically useful, decades before Epidiolex made CBD mainstream.
“The pharmacology, disposition, and metabolism of 11-hydroxy-Δ9-THC mimic that of Δ9-THC, providing evidence that Δ9-THC is converted to the 11-hydroxy compound, with the latter compound being responsible for the observed effects.”
— Louis Lemberger, Robert Crabtree, Helen Rowe
National Institute of Mental Health, Bethesda, Maryland
A single sentence in Science that explained why edibles feel different — 50 years before most consumers learned the answer
Why do edibles feel so much stronger than smoking the same amount of THC?
When you eat cannabis, THC passes through your liver before reaching your brain. The liver enzyme CYP2C9 converts a substantial fraction of the THC into 11-hydroxy-THC — a metabolite that binds CB1 receptors roughly 100 times more tightly and crosses the blood-brain barrier more efficiently. When you smoke, most THC reaches the brain directly without this conversion. The edible experience is not just "more THC" — it is a different, more potent molecule.
How long should I wait before taking more of an edible?
At least 2 hours from your first dose, though some people may take up to 3 hours to feel the full effect — especially on a full stomach. The single most common cause of bad edible experiences is taking a second dose before the first one kicks in. Our dosing guide recommends starting with 2.5-5mg THC for new users.
Do THC drinks work differently than solid edibles?
Somewhat. Liquid cannabis products, especially nano-emulsified formulations, can be absorbed more quickly through the stomach lining, partially reducing the delay compared to solid edibles. However, any orally consumed THC will undergo some first-pass liver metabolism and produce 11-OH-THC. Our comparison of THC drinks vs edibles breaks down the differences.
Can genetic differences affect how strong edibles feel?
Yes. The CYP2C9 enzyme that converts THC to 11-OH-THC varies significantly between individuals due to genetic polymorphisms. Some people are rapid metabolizers who convert more THC to the potent metabolite. Others are slow metabolizers who may absorb more THC in its original form. This genetic variation partly explains why the same edible dose can feel mild to one person and overwhelming to another.
Is 11-OH-THC the reason edibles show up longer on drug tests?
Partially. Drug tests typically detect THC-COOH (11-nor-9-carboxy-THC), the final inactive metabolite. Both THC and 11-OH-THC are eventually converted to THC-COOH. The longer duration of edible effects and the different metabolic pathway contribute to prolonged detection windows, but the primary reason THC stays detectable for weeks is that all THC metabolites are fat-soluble and stored in adipose tissue. Lemberger's 1972 paper showed excretion continuing for more than one week.
Related Research
Understanding How Your Body Processes Cannabis
Lemberger's pharmacokinetic work established the foundation for understanding cannabis metabolism, connecting to both basic science and modern clinical applications.
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni & Mechoulam (1964)
THC isolation — Lemberger's work explains what the body does with the molecule Mechoulam identified
Nabilone versus prochlorperazine for control of cancer chemotherapy-induced nausea
Herman, Chattopadhyay & Bhanumathy (1979)
Nabilone (Cesamet) — the synthetic cannabinoid that Lemberger later developed at Eli Lilly, directly descended from his THC metabolism research
Cannabis and the anxiety of fragmentation: biphasic effects
Crippa et al. (2009)
The biphasic dose-response curve — low dose calms, high dose panics — which edibles make especially treacherous because of delayed onset and higher potency
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids
Pertwee et al. (2008)
CB1 receptor pharmacology — the receptor system where 11-OH-THC binds with dramatically higher affinity than THC
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
Russo (2011)
The entourage effect review — how the body's processing of multiple cannabis compounds matters, not just isolated THC
What the researchers found
11-hydroxy-THC is pharmacologically active in humans, with effects that mimic delta-9-THC. The liver converts THC to this metabolite during first-pass metabolism, explaining the distinct pharmacology of oral cannabis consumption.
Why it matters
This paper is the molecular explanation for why edibles feel different from smoking. It has direct relevance to every person who has ever had an unexpectedly intense edible experience, every emergency room visit from edible overconsumption, and every dosing guideline for oral cannabis products.
How the study worked
Intravenous administration of radiolabeled 11-hydroxy-Δ9-THC to human volunteers, with serial measurement of plasma concentrations, psychoactive effects, and urinary/fecal excretion of the drug and metabolites over more than one week.
Who was studied
Human volunteer subjects administered intravenous 11-OH-THC
What this study cannot tell us
The 1972 study used intravenous administration of 11-OH-THC, not oral cannabis. The first-pass metabolism mechanism linking this to edible experiences was established through this and companion studies but the full oral pharmacokinetic picture was built over subsequent decades. Small sample sizes typical of 1970s human pharmacology.
How to read the evidence
This is a foundational pharmacokinetic study published in Science using direct human administration and rigorous metabolite tracking. The mechanism it described has been confirmed by decades of subsequent research and is now textbook pharmacology.
When this study was published
Published in 1972 — over 50 years old, but the pharmacokinetics it described remain the foundation of all modern cannabis edible science. The mechanism has been confirmed repeatedly.
The bigger picture
This study launched the field of cannabinoid pharmacokinetics and directly explains the distinct experience of edible cannabis — a topic of enormous practical importance as legal edible markets grow. The researcher, Louis Lemberger, later went on to develop Cesamet (nabilone, a synthetic cannabinoid antiemetic) and Prozac at Eli Lilly.
Questions still open
- ["How does individual variation in CYP2C9 enzyme activity affect edible potency?","Does CBD co-administration alter the rate of 11-OH-THC formation?","Can edible formulations be designed to bypass first-pass metabolism (sublingual, nano-emulsion)?","What is the clinical significance of the >1 week excretion period for drug testing?"]
Common questions
Why do edibles feel so much stronger than smoking?
Why do edibles take so long to kick in?
Who was Louis Lemberger?
Does this mean edibles are more dangerous?
Read the original research
11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man
Science
The most prestigious general-science journal in the world — publication here placed cannabis pharmacokinetics alongside the biggest discoveries in all of science.
Citation
Lemberger, Louis; Crabtree, Robert E; Rowe, Helen M. (1972). 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. https://doi.org/10.1126/science.177.4043.62